Cambrex (CBM) Upgraded by First Analysis to Strong-Buy

Share on StockTwits

First Analysis upgraded shares of Cambrex (NYSE:CBM) from an outperform rating to a strong-buy rating in a research report sent to investors on Friday, MarketBeat Ratings reports. They currently have $63.00 price target on the biotechnology company’s stock, down from their previous price target of $73.00.

A number of other research analysts also recently issued reports on CBM. Zacks Investment Research upgraded shares of Cambrex from a hold rating to a strong-buy rating and set a $73.00 target price on the stock in a research report on Wednesday, August 8th. Jefferies Financial Group initiated coverage on shares of Cambrex in a research report on Tuesday, September 25th. They set a buy rating and a $75.50 target price on the stock. Two research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $70.50.

Shares of Cambrex stock traded up $0.42 during trading on Friday, reaching $51.22. 674,295 shares of the company traded hands, compared to its average volume of 420,316. Cambrex has a 1-year low of $44.80 and a 1-year high of $69.43. The company has a market capitalization of $1.88 billion, a PE ratio of 15.06, a PEG ratio of 2.00 and a beta of 2.42.

Cambrex (NYSE:CBM) last released its earnings results on Thursday, November 8th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.10). Cambrex had a net margin of 20.75% and a return on equity of 22.32%. The company had revenue of $104.62 million for the quarter, compared to analyst estimates of $122.04 million. During the same quarter in the previous year, the firm earned $0.55 EPS. The firm’s revenue was down 7.1% on a year-over-year basis. On average, analysts anticipate that Cambrex will post 2.82 earnings per share for the current fiscal year.

In other Cambrex news, CFO Tom George Vadaketh sold 9,510 shares of the business’s stock in a transaction on Monday, August 20th. The shares were sold at an average price of $63.42, for a total transaction of $603,124.20. Following the completion of the sale, the chief financial officer now owns 9,510 shares in the company, valued at approximately $603,124.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven M. Klosk sold 55,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total transaction of $3,646,500.00. Following the sale, the chief executive officer now owns 138,328 shares of the company’s stock, valued at approximately $9,171,146.40. The disclosure for this sale can be found here. Insiders have sold a total of 84,510 shares of company stock valued at $5,344,824 in the last 90 days. 2.42% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Cambrex by 2.3% during the 3rd quarter. BlackRock Inc. now owns 4,731,609 shares of the biotechnology company’s stock valued at $323,642,000 after purchasing an additional 107,359 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Cambrex by 2.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,501,436 shares of the biotechnology company’s stock valued at $102,698,000 after purchasing an additional 29,470 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Cambrex by 1.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,420,580 shares of the biotechnology company’s stock valued at $74,295,000 after purchasing an additional 13,858 shares in the last quarter. American Capital Management Inc. increased its stake in Cambrex by 0.3% during the 3rd quarter. American Capital Management Inc. now owns 722,809 shares of the biotechnology company’s stock valued at $49,440,000 after purchasing an additional 2,333 shares in the last quarter. Finally, Boston Partners increased its stake in Cambrex by 3.2% during the 2nd quarter. Boston Partners now owns 699,286 shares of the biotechnology company’s stock valued at $36,572,000 after purchasing an additional 21,399 shares in the last quarter.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

See Also: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply